al. [158] demonstrated that active EGFR binds to beclin-1, inhibiting its autophagy function in non-small cell lung cancer (NSCLC), and EGFR-mutated NSCLC cells presented improved tumor progression and partial tumor resistance to therapy with tyrosine kinase inhibitors. Here, BECN1 is linked to neoplasm.